Literature DB >> 9892332

Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias.

K W Bloemenkamp1, F R Rosendaal, H R Büller, F M Helmerhorst, L P Colly, J P Vandenbroucke.   

Abstract

BACKGROUND: The magnitude of the relative risk of venous thrombosis caused by low-dose oral contraceptive use is still debated because previous studies might have been affected by diagnostic suspicion and referral bias.
METHODS: We conducted a case-control study in which the effect of diagnostic suspicion and referral bias was excluded. The study was performed in 2 diagnostic centers to which patients with clinically suspected deep vein thrombosis of the leg were referred. History of oral contraceptive use was obtained before objective testing for thrombosis. Young females with an objective diagnosis of deep vein thrombosis were considered case patients, and those who were referred with the same clinical suspicion but who had no thrombosis served as control subjects. Participants were seen between September 1, 1982, and October 18, 1995: 185 consecutive patients and 591 controls aged 15 to 49 years with a first episode of venous thrombosis and without malignant neoplasms, pregnancy, or known inherited clotting defects.
RESULTS: The overall odds ratio for oral contraceptive use was 3.2 (95% confidence interval [CI], 2.3-4.5); after adjustment for age, family history of venous thrombosis, calendar time, and center, the odds ratio was 3.9 (95% CI, 2.6-5.7). In the idiopathic group (120 patients and 413 controls, excluding recent surgery, trauma, or immobilization), the odds ratio for oral contraceptive use was 3.8 (95% CI, 2.5-5.9); after adjustment, the odds ratio was 5.0 (95% CI, 3.1-8.2).
CONCLUSIONS: In this study, in which patients and controls were subj ect to the same referral and diagnostic procedures, we found similar relative risk estimates for oral contraceptive use as in previous studies. We conclude that diagnostic suspicion and referral bias did not play an important role in previous studies and that the risk of venous thrombosis with use of current brands of oral contraceptives still exists.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9892332     DOI: 10.1001/archinte.159.1.65

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  23 in total

Review 1.  Benefits and risks of third-generation oral contraceptives.

Authors:  E S Leblanc; A Laws
Journal:  J Gen Intern Med       Date:  1999-10       Impact factor: 5.128

2.  Third generation oral contraceptives and risk of venous thrombosis: meta-analysis.

Authors:  J M Kemmeren; A Algra; D E Grobbee
Journal:  BMJ       Date:  2001-07-21

Review 3.  Cardiovascular events associated with different combined oral contraceptives: a review of current data.

Authors:  P Hannaford
Journal:  Drug Saf       Date:  2000-05       Impact factor: 5.606

Review 4.  Oral contraceptives and venous thromboembolism: a systematic review and meta-analysis.

Authors:  Lamberto Manzoli; Corrado De Vito; Carolina Marzuillo; Antonio Boccia; Paolo Villari
Journal:  Drug Saf       Date:  2012-03-01       Impact factor: 5.606

5.  Commentary: A structural approach to Berkson's fallacy and a guide to a history of opinions about it.

Authors:  Jaapjan D Snoep; Alfredo Morabia; Sonia Hernández-Díaz; Miguel A Hernán; Jan P Vandenbroucke
Journal:  Int J Epidemiol       Date:  2014-02-28       Impact factor: 7.196

Review 6.  Long-cycle treatment with oral contraceptives.

Authors:  Inka Wiegratz; Herbert Kuhl
Journal:  Drugs       Date:  2004       Impact factor: 9.546

7.  Testing bias in clinical databases: methodological considerations.

Authors:  Karin J Velthove; Hubert Gm Leufkens; Patrick C Souverein; René C Schweizer; Wouter W van Solinge
Journal:  Emerg Themes Epidemiol       Date:  2010-05-14

8.  Clinical characteristics and referral pattern of patients with left ventricular dysfunction and significant coronary artery disease undergoing radionuclide imaging.

Authors:  Jamieson M Bourque; Eric J Velazquez; Salvador Borges-Neto; Linda K Shaw; David J Whellan; Christopher M O'connor
Journal:  J Nucl Cardiol       Date:  2004 Mar-Apr       Impact factor: 5.952

9.  The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study.

Authors:  A van Hylckama Vlieg; F M Helmerhorst; J P Vandenbroucke; C J M Doggen; F R Rosendaal
Journal:  BMJ       Date:  2009-08-13

10.  Hormonal contraception and risk of venous thromboembolism: national follow-up study.

Authors:  Øjvind Lidegaard; Ellen Løkkegaard; Anne Louise Svendsen; Carsten Agger
Journal:  BMJ       Date:  2009-08-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.